DESC:A ATP BASED SOLUTION FOR APPLICATIONS IN CELL AND TISSUE STORAGE AND TRANSPLANTATIONS

FIELD OF THE INVENTION
The present invention relates to a MT-ATP solution and more particularly to the MT-ATP solution to enhance the viability and efficacy of cells or tissues.
BACKGROUND OF THE INVENTION
An adenosine-tri-phosphate (ATP) is the energy currency of life. The adenosine-tri-phosphate (ATP) powers most of the energy consuming activities of cells, such as, most anabolic reactions, joining transfer RNAs to amino acids for assembly into proteins, synthesis of nucleoside triphosphates for assembly into DNA and RNA, synthesis of polysaccharides, synthesis of fats, active transport of molecules and ions, nerve impulses, maintenance of cell volume by osmosis, adding phosphate groups (phosphorylation) to many different proteins. A mitochondrial ATP production is the main energy source for intracellular metabolic pathways. The human mitochondrial (mt) ATP synthase synthesizes the ATP from an ADP in the mitochondrial matrix using the energy provided by the proton electrochemical gradient.
WO2010099542A2 discloses solutions and compositions containing adenosine 5 '-triphosphate (ATP) or an analog thereof. In addition, the invention discloses methods of making and using the solutions and the compositions.
US6916616B2 discloses stable aqueous solutions containing one or several nucleoside triphosphates herein the respective solution has a pH value of more than 7.5 and contains no additional substances with a stabilizing effect. The nucleoside triphosphate solutions are used in particular for DNA synthesizing reactions such as, RT-PCR, cycle sequencing, random priming and nick translation.
WO2006023710A2 discloses a cosmetic or pharmaceutical composition to reduce skin damage caused by aging and/or the environment.
US20040105894A1 discloses compositions to achieve the transport of copper from the surface layers of skin into the deeper layers of skin utilizing SMW transporter molecules, and the intra-cellular storage of copper ions in the cell, for example in a bound form with glutathione, and intra-cellular transport of copper from glutathione to SOD apoprotein by metallochaperones; and the supply of energetic molecules, such as ATP, ADP, or phosphorylated saccharides for SOD metallochaperones to perform their intra-cellular metal transfer function.
Hair fall is a common problem. The Hair fall occurs when the normal cycle of hair growth and shedding is disrupted or when one or more hair follicles are destroyed. The cause of hair loss involves one or more factors, such as, family history (heredity), hormonal changes, medical conditions, and medications. None of the above mentioned prior art discloses the ATP solutions to enhance tissue or cell engraftment efficacy and viability of cells and hence there is need for the present Invention.
SUMMARY OF THE PRESENT INVENTION
The present invention relates to a MT-ATP solution and more particularly to the MT-ATP solution to enhance the viability and efficacy of cells. The MT-ATP is an energy delivering solution to the cells, tissues, and follicles. The MT-ATP solution contains an adenosine-tri-phosphate (ATP), a polyethylene glycol (PEG), a benzalkonium chloride (BKC), an amoxycillin, a buffer solution BPS or a normal saline, and one or more minimum essential amino acids. The concentration of the adenosine-tri-phosphate (ATP) in the solution is selected from a range of 0.5mM to 5mM. The concentration of the polyethylene glycol (PEG) in the solution is selected from a range of 2mM to 12mM. The concentration (v/v) of the benzalkonium chloride in the solution is selected from a range of 0.5% to 5.0%. The concentration (w/v) of the amoxycillin in the solution is selected from a range of 0.1 % to 0.5%.
Another embodiment of the present invention provides a MT-ATP solution including an adenosine-tri-phosphate (ATP), a polyethylene glycol (PEG), one or more minimal essential nutrients, a benzalkonium chloride (BKC), and one or more growth factors (GFs).
One advantage of the present invention is to provide the MT-ATP solution for dipping hair follicles prior to transplantation.
Another advantage of the present invention is to provide the MT-ATP solution for storage and preservation of the grafts without losing functionality.
Yet another advantage of the present invention is to provide the MT-ATP solution for quick recovery of wounds or injuries, better graft retention and enhancing hair follicular growth post the transplantation.
Another advantage of the present invention is to provide the MT-ATP along with PRP/PRFM/DIPONED-GFC for a significant follicular graft retention post transplantation and hair growth over 6 to 12 months period.
Further objectives, advantages and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example and appropriate reference to accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention can be understood in more detail by reading the subsequent detailed description in conjunction with the examples and references made to the accompanying drawings, wherein:
FIG. 1 is a graphical representation of the example 1 of the present invention.
FIG. 2 is a graphical representation of the example 2 of the present invention.
FIG. 3 is a schematic representation of the example 2 of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
While this invention is susceptible to embodiment in many different forms, there is shown in the drawings and will herein be described in detail specific embodiments, with the understanding that the present disclosure of such embodiments is to be considered as an example of the principles and not intended to limit the invention to the specific embodiments shown and described. In the description below, like reference numerals are used to describe the same, similar or corresponding parts in the several views of the drawings. This detailed description defines the meaning of the terms used herein and specifically describes embodiments in order for those skilled in the art to practice the invention.
Definition
The terms “about” and “essentially” mean ±10 percent.
The terms “a” or “an”, as used herein, are defined as one or as more than one. The term “plurality”, as used herein, is defined as two or as more than two. The term “another”, as used herein, is defined as at least a second or more. The terms “including” and/or “having”, as used herein, are defined as comprising (i.e., open language). The term “coupled”, as used herein, is defined as connected, although not necessarily directly, and not necessarily mechanically.
The term “comprising” is not intended to limit inventions to only claiming the present invention with such comprising language. Any invention using the term comprising could be separated into one or more claims using “consisting” or “consisting of” claim language and is so intended. The term “comprising” can be used interchangeably used by the terms “having” or “containing”.
Reference throughout this document to “one embodiment”, “certain embodiments”, “an embodiment”, “another embodiment”, and “yet another embodiment” or similar terms means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of such phrases or in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments without limitation.
The term “or” as used herein is to be interpreted as an inclusive or meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.
The drawings featured in the figures are for the purpose of illustrating certain convenient embodiments of the present invention, and are not to be considered as limitation thereto. Term “means” preceding a present participle of an operation indicates a desired function for which there is one or more embodiments, i.e., one or more methods, devices, or apparatuses for achieving the desired function and that one skilled in the art could select from these or their equivalent in view of the disclosure herein and use of the term “means” is not intended to be limiting.
As used herein, the term "pharmaceutical composition" generally refers to, but not limited to, a composition that is pharmaceutically acceptable.
As used herein, the term "pharmaceutically acceptable" generally refers to, but not limited to, those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
As used herein, the term "solution" generally refers to, but not limited to, a chemically and physically homogeneous mixture of two or more substances. The solution may comprise a solid dispersed in a liquid, solid or semi-solid medium. Preferably the solution comprises a solid in a liquid medium. The solution can also be mixed with extracellular matrix proteins like collagen, fibrinogen, hyaluronic acid and different growth factors like IGF, EGF, FGF and alike.
As used herein, the term "ATP" generally refers to, but not limited to, a nucleotide that consists of three main structures: a nitrogenous base, an adenine; a sugar, a ribose; and a chain of three phosphate groups bound to the ribose. The phosphate tail of the adenosine-tri-phosphate (ATP) is the actual power source of the cell. Available energy is contained in the bonds between the phosphates and is released when they are broken, which occurs through the addition of a water molecule (a process called hydrolysis). Usually only the outer phosphate is removed from the adenosine-tri-phosphate (ATP) to yield energy; when this occur the adenosine-tri-phosphate (ATP) is converted to adenosine diphosphate (ADP), the form of the nucleotide having only two phosphates.
As used herein, the term “MT” generally refers to, but not limited to, meresis therapeutics.
As used herein, the term “polyethylene glycol” generally refers to, but not limited to, a synthetic polyether that is available in a range of molecular weights. The term “polyethylene glycol” is interchangeably used by “PEG”, poly(oxyethylene) or poly(ethylene oxide). Materials with Mw <100,000 are usually called PEGs, while higher molecular weight polymers are classified as poly(ethylene oxide). These polymers are amphiphilic and soluble in water as well as in many organic solvents (e.g., methylene chloride, ethanol, toluene, acetone, and chloroform). Low molecular weight (Mw <1,000) PEGs are viscous and colorless liquids, while higher molecular weight PEGs are waxy, white solids with melting points proportional to their molecular weights to an upper limit of about 67 °C. The polyethylene glycol (PEG) has been found to be nontoxic and is approved by the FDA for use as excipients or as a carrier in different pharmaceutical formulations, foods, and cosmetics.
As used herein, the term “benzalkonium chloride” generally refers to, but not limited to, a quaternary ammonium antiseptic and disinfectant with actions and uses similar to those of other cationic surfactants. It is also used as an antimicrobial preservative for pharmaceutical products. For most multidose aqueous nasal, ophthalmic and optic products, benzalkonium chloride (BKC) is the preservative of choice. The benzalkonium chloride (BKC) being used in ophthalmic solutions at a 39 concentration of 0.01-0.02%. The benzalkonium chloride (BKC) is an effective bactericidal and fungicidal agent that helps to minimize the growth of organisms in multidose containers.
As used herein, the term “buffer solution” generally refers to a solution which resists changes in pH when small quantities of an acid or an alkali are added to it. The buffer solution is selected from an acidic buffer solution and an alkaline buffer solution.
As used herein, the term “phosphate buffered saline” or “(PBS)” generally refers to a salty solution containing a sodium chloride, a sodium phosphate, and (in some formulations) a potassium chloride and a potassium phosphate. The phosphate buffered saline (PBS) has many uses because it is isotonic and non-toxic to cells. The phosphate buffered saline (PBS) can be used to dilute substances, to rinse containers containing cells, as a diluents in methods to dry biomolecules.
As used herein, the term “normal saline” generally refers to a 0.9% sodium chloride solution. The normal saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. A pH of normal saline is in a range of 4.5 to 7.0.
As used herein, the term “essential nutrient” generally refers to, but not limited to, a nutrient that the body cannot synthesize on its own or not to an adequate amount and must be provided by the diet. These nutrients are necessary for the body to function properly. The six essential nutrients include carbohydrates, protein, fat, vitamins, minerals and water.
As used herein, the term “essential amino acid” generally refers to an amino acid that cannot be synthesized by the organism, but must be supplied in its diet. The essential amino acids are selected from, but not limited to, a phenylalanine, a valine, a threonine, a tryptophan, a methionine, a leucine, an isoleucine, a lysine, a histidine, an arginine, a cysteine, a glycine, a glutamine, a proline, a tyrosine, an alanine, an aspartic acid, an asparagine, a glutamic acid, a pyrrolysine and a serine.
As used herein, the term “growth factors” generally refers to, but not limited to, a substance capable of stimulating cellular growth, proliferation, healing, and cellular differentiation. Usually the growth factors are a protein or a steroid hormone. The growth factors are important for regulating a variety of cellular processes. The growth factors is selected from the group, but not limited to, an adrenomedullin (AM), an angiopoietin (Ang), an autocrine motility factor, a bone morphogenetic proteins (BMPs), a brain-derived neurotrophic factor (BDNF), an epidermal growth factor (EGF), an erythropoietin (EPO), a fibroblast growth factor (FGF), a foetal bovine somatotrophin (FBS), a glial cell line-derived neurotrophic factor (GDNF), a granulocyte colony-stimulating factor (G-CSF), a granulocyte macrophage colony-stimulating factor (GM-CSF), a growth differentiation factor-9 (GDF9), a hepatocyte growth factor (HGF), a hepatoma-derived growth factor (HDGF), an insulin-like growth factor (IGF), a keratinocyte growth factor (KGF), a migration-stimulating factor (MSF), a myostatin (GDF-8), a nerve growth factor (NGF) and other neurotrophins, a platelet-derived growth factor (PDGF), a thrombopoietin (TPO), a t-cell growth factor (TCGF), a transforming growth factor alpha(TGF-a), a transforming growth factor beta(TGF-ß), a tumor necrosis factor-alpha(TNF-a), a vascular endothelial growth factor (VEGF), a placental growth factor (PGF), an IL-1, an IL-2, an IL-3, an IL-4, an IL-5-, an IL-6, an IL-7, a renalase-RNLS-Anti-apoptotic survival factor. The growth factors in platelets are selected from the group, but not limited to, PDGF, IGF-1, EGF, and TGF-ß.
As used herein, the term "weight per volume” or “(w/v)" generally refers to, but not limited to, the relationship of a solute to a solvent expressed as grams of solute per milliliter of the total solution.
As used herein, the term "volume per volume” or “(v/v)" generally refers to, but not limited to, a measure of concentration of a substance in solution expressed as the ratio of the volume of the solution to the total volume of the solution multiplied by 100%.
As used herein, the term "amoxycillin” generally refers to, but not limited to, a semi-synthetic penicillin closely related to ampicillin and with similar properties, but more readily absorbed when taken orally. The amoxycillin includes, but not limited to, a penicillin, a ampicillin, a erythromycin, a streptomycin, a sulphonamide, a tetracycline, a sulfa drug, a wonder drug, a amoxil, a larotid, a polymox, a augmentin.
As used herein, the term “cell” generally refers to, but not limited to, a basic structural, functional, and biological unit of living organisms. The cell is selected from, but not limited to, a salivary gland cell, a von ebner's gland cell, a mammary gland cell, a lacrimal gland cell, a ceruminous gland cell in ear, a eccrine sweat gland dark cell, a eccrine sweat gland clear cell, an apocrine sweat gland cell, a gland of moll cell in eyelid, a sebaceous gland cell (lipid-rich sebum secretion), a bowman's gland cell in nose, a brunner's gland cell, a seminal vesicle cell, a prostate gland cell, a bulbourethral gland cell, a bartholin's gland cell, a gland of littre cell, an uterus endometrium cell, an isolated goblet cell of respiratory and digestive tracts, a stomach lining mucous cell, a gastric gland zymogenic cell, a gastric gland oxyntic cell, a pancreatic acinar cell, a paneth cell of small intestine, a type II pneumocyte of lung, a clara cell of lung, an anterior pituitary cell, an intermediate pituitary cell, secreting melanocyte-stimulating hormone, a agnocellular neurosecretory cell, a gut and respiratory tract cell, a thyroid gland cell, a parathyroid gland cell, an adrenal gland cell, a leydig cell of testes secreting testosterone, a theca interna cell of ovarian follicle secreting estrogen, a corpus luteum cell of ruptured ovarian follicle secreting progesterone, a juxtaglomerular cell (renin secretion), a macula densa cell of kidney, a peripolar cell of kidney, a mesangial cell of kidney, an inner pillar cell of organ of corti, an outer pillar cell of organ of corti, an inner phalangeal cell of organ of corti, an outer phalangeal cell of organ of corti, a border cell of organ of corti, a hensen cell, a vestibular apparatus supporting cell, a taste bud supporting cell, a olfactory epithelium supporting cell, a schwann cell, a satellite glial cell, a enteric glial cell, an astrocyte, a neuron cells, an oligodendrocyte, a spindle neuron, an anterior lens epithelial cell, a crystalline containing lens fiber cell, a hepatocyte, an adipocytes, a liver lipocyte, a kidney parietal cell, a kidney glomerulus podocyte, a kidney proximal tubule brush border cell, a loop of henle thin segment cell, a kidney distal tubule cell, a kidney collecting duct cell, a pancreatic duct cell, a nonstriated duct cell, a duct cell, an intestinal brush border cell, an exocrine gland striated duct cell, a gall bladder epithelial cell, a ductulus efferens nonciliated cell, an epididymal principal cell, an epididymal basal cell, an ameloblast epithelial cell, a planum semilunatum epithelial cell, an organ of corti interdental epithelial cell, a loose connective tissue fibroblasts, a corneal fibroblasts, a tendon fibroblasts, a bone marrow reticular tissue fibroblasts, another nonepithelial fibroblasts, a pericyte, a nucleus pulposus cell of intervertebral disc, a cementoblast/cementocyte, an odontoblast/odontocyte, a hyaline cartilage chondrocyte, a fibrocartilage chondrocyte, an elastic cartilage chondrocyte, an osteoblast/osteocyte, an osteoprogenitor cell, an epidermal keratinocyte , an epidermal basal cell, a keratinocyte of fingernails and toenails, a nail bed basal cell, a medullary hair shaft cell, a cortical hair shaft cell, a cuticular hair shaft cell, a cuticular hair root sheath cell, a hair root sheath cell of huxley's layer, a hair root sheath cell of henle's layer, a external hair root sheath cell, a hair matrix cell, a surface epithelial cell of stratified squamous epithelium of cornea, tongue, oral cavity, esophagus, anal canal, distal urethra and vagina, a basal cell (stem cell) of epithelia of cornea, tongue, oral cavity, esophagus, anal canal, distal urethra and vagina, an urinary epithelium cell, an auditory inner hair cell of organ of corti, an auditory outer hair cell of organ of corti, a basal cell of olfactory epithelium, a cold-sensitive primary sensory neurons, a heat-sensitive primary sensory neurons, a merkel cell of epidermis, an olfactory receptor neuron, a pain-sensitive primary sensory neurons, a photoreceptor cells of retina in eye, a proprioceptive primary sensory neurons, a touch-sensitive primary sensory neurons, a type I carotid body cell, a type II carotid body cell, a type I hair cell, a type II hair cell, a type I taste bud cell, a cholinergic neural cell, an adrenergic neural cell, a peptidergic neural cell. More preferably the cell is the stem cell.
As used herein, the term “stem cells” generally refers to, but not limited to, undifferentiated biological cells that can differentiate into specialized cells and can divide through mitosis to produce more stem cells. The stem cells are of two types, an embryonic stem cell and an adult stem cell. The embryonic stem cells are derived from a four- or five-day-old human embryo that is in the blastocyst phase of development. The adult stem cells exist throughout the body after embryonic development and are found inside of different types of tissue. These stem cells have been found in tissues such as the brain, bone marrow, blood, blood vessels, skeletal muscles, skin, and the liver. The stem cells remain in a quiescent or non-dividing state for years until activated by disease or tissue injury.
As used herein, the term “tissue” generally refers to, but not limited to, an ensemble of similar cells from the same origin that together carry out a specific function. The tissue are selected from, but not limited to, a connective tissue, a muscle tissue, a nervous tissue, an epithelial tissue, a mineralized tissue, a meristematic tissue, a permanent tissue, a simple tissue, a parenchyma, a collenchyma, a sclerenchyma, an epidermis, a xylem and a phloem.
As used herein, the term “follicle” generally refers to, but not limited to, a small spherical group of cells containing a cavity. The follicle is selected from, a dental follicle, a hair follicle, a lymph follicle, an ovarian follicle, a thyroid follicle. More preferably, the follicle is a hair follicle.
The present invention relates to a MT-ATP solution and more particularly to the MT-ATP solution to enhance the viability and efficacy of cells. The MT-ATP is energy or nutrients delivering solution to the cells, tissues, and follicles. The MT-ATP solution contains an adenosine-tri-phosphate (ATP), a polyethylene glycol (PEG), a benzalkonium chloride (BKC), an amoxycillin, a buffer solution BPS or a normal saline, and one or more minimum essential amino acids. The concentration of the adenosine-tri-phosphate (ATP) in the solution is selected from a range of 0.5mM to 5mM, more preferably the concentration of the adenosine-tri-phosphate (ATP) in the solution is 2mM. The concentration of the polyethylene glycol (PEG) in the solution is selected from a range of 2mM to 12mM, more preferably the concentration of the polyethylene glycol (PEG) in the solution is 8mM. The concentration (v/v) of the benzalkonium chloride (BKC) in the solution is selected from a range of 0.5% to 5.0%, more preferably the concentration (v/v) of the benzalkonium chloride (BKC) in the solution is 1.5%. The concentration (w/v) of the amoxycillin in the solution is selected from a range of 0.1 % to 0.5%, more preferably concentration (w/v) of the amoxycillin in the solution is 1.5%.
Another embodiment of the present invention provides a MT-ATP solution including an adenosine-tri-phosphate (ATP), a polyethylene glycol (PEG), one or more minimal essential nutrients, a benzalkonium chloride (BKC), and one or more growth factors (GFs).
Yet another embodiment of the present invention provides a MT-ATP solution including 2mM adenosine-tri-phosphate (ATP), 8mM polyethylene glycol (PEG), 0.2 % (w/v) amoxycilin, 1.5% (v/v) benzalkonium Chloride (BKC), a buffer solution BPS or a normal saline and one or more minimum essential amino acids.
The MT-ATP has classically been considered as the cells primary energy currency and helps keeping stem cells in good shape. The polyethylene glycol (PEG) has limited toxicity to the cells and is used for the effective delivery of nutrients, GFs, and the adenosine-tri-phosphate (ATP) to the stem cells. The benzalkonium chloride (BKC) works as a topical antiseptic and keeps the MT-ATP solution away from any microbial contaminations. Finally a rich medium is used which contains key nutritional components for the cells and thus enhance the viability and efficacy of different kinds of stem cells, other cell types, and hair follicles. The MT-ATP solution is pharmaceutically acceptable composition.
The synergetic effect of adenosine-tri-phosphate (ATP) along with minimum essential amino acids enhances tissue or cell engraftment efficacy.
The present invention further discloses a method of enhancing efficacy of hair growth. The method includes, firstly, pouring the MT-ATP solution to a sterile petri-plate. The solution is selected from a range of 1ml to 40ml. preferably, 20ml solution is used. Secondly, dipping hair grafts containing follicles into the solution. The hair grafts are selected from a range of, but not limited to 1 to 5000. Preferably the number of hair grafts selected is about 1000. The order of the first and the second steps can be performed interchangeably. Thirdly, the grafts being stored at the temperature range from 1°C to 10° C, the preferable at the temperature of 4°C. The hair grafts are kept for a time range of 40 to 60 hours, preferably the grafts are kept for 48 hours.
One advantage of the present invention is to provide the MT-ATP solution for dipping hair follicles prior to the transplantation.
Another advantage of the present invention is to provide The MT-ATP solution for storage and preservation of the grafts without losing functionality and without using a cryopreservation method.
Yet another advantage of the present invention is to provide the MT-ATP solution for quick recovery of the injuries, better graft retention and enhancing hair follicular growth.

Example 1
Fig. 1 illustrates a graphical representation of viability of hair follicular stem cells assessed at room temperature. The X-axis of the graph represented time points and y-axis of the graph represented % variability. The freshly isolated stem cells from hair follicles were cultured and preserved in DMEM in presence of absence (control) of polyethylene glycol(PEG) (8mM) and adenosine-tri-phosphate (ATP) (2mM) up to 48 Hours. Viability measurements were measured at time interval of 0 hours, 24 hours, and 48 hours by trypan blue exclusion method. The experimental results displayed that adding MT-ATP solution enhanced the viability and growth of hair follicles.
Example 2
Fig. 2 illustrates a graphical representation of a method of enhancing efficacy of hair growth. A 20ml MT-ATP solution was poured in a sterile petri-plate prior to the transplantation. 1000 hair grafts were dipped into the MT-ATP solution and stored at 4° C for 48 hours. The X-axis of the graph represented period of intervention and y-axis of the graph represented hair follicle numbers. Fig. 3 illustrates a schematic representation of the result in accordance with the experiment 1 and experiment 2.
Those skilled in the art to which the present invention pertains may make modifications resulting in other embodiments employing principles of the present invention without departing from its spirit or characteristics, particularly upon considering the foregoing teachings. Accordingly, the described embodiments are to be considered in all respects only as illustrative, and not restrictive, and the scope of the present invention is, therefore, indicated by the appended claims rather than by the foregoing description or drawings. Consequently, while the present invention has been described with reference to particular embodiments, modifications of structure, sequence, materials and the like apparent to those skilled in the art still fall within the scope of the invention as claimed by the applicant.
,CLAIMS:1. A MT-ATP solution for enhancing viability and efficacy of cells, the solution comprising:
an adenosine-tri-phosphate (ATP), the adenosine tri phosphate(ATP) concentration in range of 0.5mM to 5mM;
a polyethylene glycol (PEG), the polyethylene glycol (PEG) concentration in range of 2mM to 12mM;
a benzalkonium chloride (BKC), the benzalkonium chloride (BKC) concentration in range of 0.5% to 5.0%;
an amoxycillin, the amoxycillin concentration in range of 0.1 % to 0.5%;
a buffer solution; and
an at least one minimum essential amino acid.

2. The solution as claimed in claim 1, wherein the adenosine-tri-phosphate (ATP) concentration is 2mM.

3. The solution as claimed in claim 1, wherein the polyethylene glycol (PEG) concentration is 8mM.

4. The solution as claimed in claim 1, wherein the benzalkonium chloride (BKC) concentration is 1.5%.

5. The solution as claimed in claim 1, wherein the amoxycillin concentration is 1.5%.

6. The solution as claimed in claim 1, where in the MT-ATP solution is selected in a range between 1 ml to 40 ml.

7. A MT-ATP solution for enhancing viability and efficacy of the cells, the solution comprising:
an adenosine-tri-phosphate (ATP), the adenosine tri phosphate(ATP) concentration is 2mM;
a polyethylene glycol (PEG), the polyethylene glycol (PEG) concentration is 8mM;
a benzalkonium chloride (BKC), the benzalkonium chloride (BKC) concentration is 1.5%;
an amoxycillin, the amoxycillin concentration is 1.5%;
a buffer solution; and
an at least one minimum essential amino acid.

8. A method for enhancing viability and efficacy of the cells, the method comprising:
a MT-ATP solution having:
an adenosine-tri-phosphate (ATP), the adenosine tri-phosphate (ATP) concentration in range of 0.5mM to 5mM;
a polyethylene glycol (PEG), the polyethylene glycol (PEG) concentration in range of 2mM to 12mM;
a benzalkonium chloride (BKC), the benzalkonium chloride (BKC) concentration in range of 0.5% to 5.0%;
an amoxycillin, the amoxycillin concentration in range of 0.1 % to 0.5%;
a buffer solution; and
an at least one minimum essential amino acid,
wherein the MT-ATP solution is poured in an at least one sterile petri plate, an at least one hair graft having an at least one follicle dipped is in the MT-ATP solution, and further the at least one hair graft having the at least one follicle is stored within temperature range of 1°C to 10°C for a period of 40 to 60 hours.

9. The solution as claimed in claim 8, where in the MT-ATP solution is selected in a range between 1 ml to 40 ml.

10. The solution as claimed in claim 8, wherein the at least one hair graft is selected in a range between 1 to 5000.